Patents by Inventor Gabriel Lazarus

Gabriel Lazarus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11890047
    Abstract: Methods for treating anxiety disorders and for reducing a risk associated with developing an anxiety disorder in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with anxiety disorders as well as an increased risk of developing an anxiety disorder. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to an anxiety disorder status in the patient. Other aspects are directed to reducing a likelihood of developing an anxiety disorder in patients presenting one or more anxiety disorder risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's anxiety disorder status or risk of developing an anxiety disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: February 6, 2024
    Assignee: Medtronic Ireland Manufacturing Unlimited Company
    Inventors: Gabriel Lazarus, Douglas A. Hettrick
  • Patent number: 11844558
    Abstract: Methods for treating eating disorders and for reducing a risk associated with developing an eating disorder in patients via therapeutic renal neuromodulation and associated systems. Renal sympathetic nerve activity can be attenuated to improve a patient's eating disorder status or risk of developing an eating disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to modulate the renal sympathetic nerve.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: December 19, 2023
    Assignee: Medtronic Ireland Manufacturing Unlimited Company
    Inventors: Gabriel Lazarus, Douglas A. Hettrick
  • Publication number: 20220370112
    Abstract: Methods for treating eating disorders and for reducing a risk associated with developing an eating disorder in patients via therapeutic renal neuromodulation and associated systems. Renal sympathetic nerve activity can be attenuated to improve a patient's eating disorder status or risk of developing an eating disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to modulate the renal sympathetic nerve.
    Type: Application
    Filed: July 27, 2022
    Publication date: November 24, 2022
    Inventors: Gabriel Lazarus, Douglas A. Hettrick
  • Patent number: 11413084
    Abstract: Methods for treating eating disorders and for reducing a risk associated with developing an eating disorder in patients via therapeutic renal neuromodulation and associated systems. Renal sympathetic nerve activity can be attenuated to improve a patient's eating disorder status or risk of developing an eating disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to modulate the renal sympathetic nerve.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: August 16, 2022
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Gabriel Lazarus, Douglas Hettrick
  • Patent number: 11284934
    Abstract: Methods for treating sleep disorders and for reducing a risk associated with developing a sleep disorder in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with sleep disorders as well as an increased risk of developing a sleep disorder. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to a sleep disorder status in the patient. Other aspects are directed to reducing a likelihood of developing a sleep disorder in patients presenting one or more sleep disorder risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's sleep disorder status or risk of developing a sleep disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: March 29, 2022
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Gabriel Lazarus, Douglas Hettrick
  • Patent number: 11116564
    Abstract: Methods for treating anxiety disorders and for reducing a risk associated with developing an anxiety disorder in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with anxiety disorders as well as an increased risk of developing an anxiety disorder. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to an anxiety disorder status in the patient. Other aspects are directed to reducing a likelihood of developing an anxiety disorder in patients presenting one or more anxiety disorder risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's anxiety disorder status or risk of developing an anxiety disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: September 14, 2021
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Gabriel Lazarus, Douglas Hettrick
  • Publication number: 20210267661
    Abstract: Methods for treating anxiety disorders and for reducing a risk associated with developing an anxiety disorder in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with anxiety disorders as well as an increased risk of developing an anxiety disorder. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to an anxiety disorder status in the patient. Other aspects are directed to reducing a likelihood of developing an anxiety disorder in patients presenting one or more anxiety disorder risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's anxiety disorder status or risk of developing an anxiety disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.
    Type: Application
    Filed: May 19, 2021
    Publication date: September 2, 2021
    Inventors: Gabriel Lazarus, Douglas A. Hettrick
  • Patent number: 10646713
    Abstract: Methods for reducing a risk associated with developing cognitive impairment, including dementia, with therapeutic renal neuromodulation and associated systems and methods are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with an increased risk of developing dementia in later life. One aspect of the present technology is directed to methods for improving a patient's calculated risk score for developing dementia. Other aspects of the present technology are directed to reducing a likelihood of developing dementia in patients presenting one or more dementia risk factors in middle age. Renal sympathetic nerve activity can be attenuated to improve a patient's risk of developing dementia. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: May 12, 2020
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Douglas Hettrick, Gabriel Lazarus
  • Publication number: 20200008855
    Abstract: Methods for treating eating disorders and for reducing a risk associated with developing an eating disorder in patients via therapeutic renal neuromodulation and associated systems. Renal sympathetic nerve activity can be attenuated to improve a patient's eating disorder status or risk of developing an eating disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to modulate the renal sympathetic nerve.
    Type: Application
    Filed: June 28, 2019
    Publication date: January 9, 2020
    Inventors: Gabriel Lazarus, Douglas Hettrick
  • Publication number: 20190009077
    Abstract: Methods for treating anxiety disorders and for reducing a risk associated with developing an anxiety disorder in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with anxiety disorders as well as an increased risk of developing an anxiety disorder. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to an anxiety disorder status in the patient. Other aspects are directed to reducing a likelihood of developing an anxiety disorder in patients presenting one or more anxiety disorder risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's anxiety disorder status or risk of developing an anxiety disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.
    Type: Application
    Filed: July 3, 2018
    Publication date: January 10, 2019
    Inventors: Gabriel Lazarus, Douglas Hettrick
  • Publication number: 20190008577
    Abstract: Methods for treating sleep disorders and for reducing a risk associated with developing a sleep disorder in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with sleep disorders as well as an increased risk of developing a sleep disorder. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to a sleep disorder status in the patient. Other aspects are directed to reducing a likelihood of developing a sleep disorder in patients presenting one or more sleep disorder risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's sleep disorder status or risk of developing a sleep disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g.
    Type: Application
    Filed: July 3, 2018
    Publication date: January 10, 2019
    Inventors: Gabriel Lazarus, Douglas Hettrick
  • Publication number: 20180236235
    Abstract: Methods for reducing a risk associated with developing cognitive impairment, including dementia, with therapeutic renal neuromodulation and associated systems and methods are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with an increased risk of developing dementia in later life. One aspect of the present technology is directed to methods for improving a patient's calculated risk score for developing dementia. Other aspects of the present technology are directed to reducing a likelihood of developing dementia in patients presenting one or more dementia risk factors in middle age. Renal sympathetic nerve activity can be attenuated to improve a patient's risk of developing dementia. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g.
    Type: Application
    Filed: April 7, 2017
    Publication date: August 23, 2018
    Inventors: Douglas Hettrick, Gabriel Lazarus